An Australian pharmaceutical company is asking regulators to consider a THC-free cannabidiol tablet as a prescription treatment for pain after completing a Phase 3 randomized clinical trial involving 155 adults. Developed by Promethean BioPharma and manufactured by Sydney-based TCann, the sublingual tablet delivers purified cannabidiol without tetrahydrocannabinol, potentially offering a cannabinoid medicine without the intoxicating effects associated with THC. Company materials say the results were presented to Australia’s Therapeutic Goods Administration in July 2026 as the developers pursue a regulatory pathway that could eventually result in formal registration of the medicine.
The development has attracted attention because an approved CBD pain tablet would be a significant departure from the largely unregistered cannabis products currently prescribed in Australia. But the most important finding from the trial is also the one that requires the most attention: the CBD tablet did not outperform placebo on the study’s primary pain endpoint. TCann acknowledges this directly in its investor materials, while reporting that an exploratory subgroup representing roughly 10 percent of participants experienced substantially greater pain reductions. Those subgroup findings are scientifically interesting and could guide another trial, but they cannot be treated as evidence that the Phase 3 study successfully demonstrated efficacy.
The Phase 3 Trial Tested 150 Milligrams of CBD Per Day
The trial is registered with the Australian New Zealand Clinical Trials Registry as ACTRN12623000404628. It was designed as a randomized, double-blind, placebo-controlled, parallel-arm Phase 3 study evaluating the efficacy, safety and tolerability of sublingual CBD in adults with mild-to-moderate non-palliative pain. Participants could have acute, subacute or chronic pain that had persisted for at least two weeks. The registered intervention delivered a total of 150 mg of CBD each day, divided across three daily doses spaced approximately six hours apart. Researchers selected that daily dose partly because 150 mg represents the upper limit established for Australia’s low-dose Schedule 3 CBD framework.
Company disclosures indicate that 155 adults ultimately participated and that the study lasted approximately eight weeks overall, including four weeks of active treatment. Its principal efficacy measure was change from baseline on the Brief Pain Inventory Short Form pain-severity score, a widely used patient-reported scale assessing pain intensity. Participants could continue some conventional medications such as paracetamol, reflecting more closely how a future CBD treatment might be used alongside ordinary pain management rather than in complete isolation.
The Primary Result Was Negative
Despite the attention surrounding the regulatory application, TCann’s own disclosure says plainly that the trial failed its primary endpoint. When researchers compared the entire CBD treatment group with placebo, the CBD tablet did not produce a statistically convincing advantage in the prespecified primary pain outcome. CEO Peter Comerford said that the overall result did not outperform placebo sufficiently to meet the study’s primary goals.
That finding is crucial when interpreting headlines saying the tablet “worked” or is now approaching approval. Completing a Phase 3 trial is not the same as successfully completing one. Phase 3 refers to the stage and design of development, not whether a medicine demonstrated efficacy. A negative primary endpoint normally creates a substantial regulatory obstacle because the primary analysis is determined before researchers see the results specifically to reduce the risk that chance patterns in the data will be mistaken for genuine treatment effects. The TGA—not the manufacturer—will ultimately decide whether the total package provides sufficient evidence to justify further evaluation or some form of provisional registration. The regulator makes clear that entry into its provisional pathway does not guarantee eventual registration.
About 10 Percent of Participants Appeared to Be Strong Responders
What keeps the research scientifically interesting is what investigators found after looking more closely at the data. TCann reports that an exploratory analysis identified a group comprising approximately 10 percent of participants who showed unusually strong pain responses. According to the company, these patients experienced improvement beginning during the first week and maintained it across the four-week treatment period, with reductions of roughly two to four points on the Brief Pain Inventory Short Form.
There is an important methodological limitation: the responder analysis was not prespecified before the trial began. Post-hoc analyses can reveal valuable biological clues, particularly if a medicine may work for a specific subtype of patient rather than everyone with a broadly defined condition. But they are vulnerable to chance findings because researchers can examine many patterns after seeing the data. The appropriate next step is therefore not to conclude that CBD has already been proven effective for that 10 percent, but to design a new trial that defines the suspected responder population beforehand and tests whether the effect can be reproduced. TCann says the responder pattern is now influencing the design of future clinical studies.
The THC-Free Formulation Is Designed to Behave More Like a Conventional Medicine
The tablet is technically different from many cannabis oils currently prescribed in Australia. Promethean says its formulation uses very small particles dispersed in a water-compatible system intended to improve absorption and provide more predictable dosing. Company materials describe particles of approximately 40 nanometers that can be dried and compressed into a conventional tablet. Promethean has promoted the technology as providing faster absorption than traditional oil formulations, although those bioavailability claims should be distinguished from evidence that the product actually relieves pain—the Phase 3 efficacy trial addressed the latter question and did not show superiority across the full study population.
The absence of THC is also important. THC produces most of cannabis’s familiar intoxicating effects and creates practical concerns involving impairment and drug testing that do not apply in the same way to purified CBD. Australia’s current TGA product database classifies medicinal cannabis containing at least 98 percent CBD as Category 1, while products containing larger proportions of THC fall into progressively different categories. The September 2026 TGA list already includes TCann CBD tablets among unapproved medicinal cannabis products available through special-access pathways. That listing is not equivalent to approval for pain or inclusion on the Australian Register of Therapeutic Goods.
The Safety Findings Were More Encouraging Than the Efficacy Results
TCann says the Phase 3 study identified no significant new safety signal, toxicity problem or product-quality issue among the 155 participants. Independent news reports have likewise described the trial as producing generally reassuring short-term safety results. That is potentially important because a non-intoxicating cannabinoid treatment intended for everyday pain management would need an attractive safety profile to compete with established analgesics.
At the same time, 155 participants followed for several weeks cannot establish the safety of long-term use or reliably detect uncommon adverse reactions. CBD is generally well tolerated at moderate doses, but it is pharmacologically active rather than harmless. Systematic reviews have identified diarrhea, somnolence and sedation among reported adverse effects and have documented interactions with medications metabolized through liver enzymes. A meta-analysis of cannabidiol-associated liver injury found that the strongest risk occurred with substantially higher CBD doses and concurrent antiepileptic medicines; notably, that analysis found no liver-injury cases among adults receiving less than 300 mg per day, placing the Australian trial’s 150-mg dose below the range associated with the greatest observed risk.
The Broader Evidence for CBD Alone as a Painkiller Remains Mixed
The negative primary result also fits an uncomfortable pattern in the CBD literature. A 2024 review published in The Journal of Pain examined 16 randomized trials of pharmaceutical-grade CBD in which pain was an outcome and reported that 15 failed to show greater analgesic benefit than placebo. The authors concluded that convincing clinical evidence supporting CBD alone as an analgesic remained absent despite extensive consumer interest.
Other researchers have interpreted the literature more optimistically. A separate 2024 systematic review examining clinical and preclinical CBD research concluded that CBD has plausible analgesic and anti-inflammatory mechanisms and may benefit some forms of pain, while also acknowledging that controlled human evidence remains limited and that considerably more CBD-only clinical research is needed. Australia’s own TGA guidance similarly shows that much of the earlier cannabinoid pain literature involved THC-containing products, mixed THC/CBD formulations or relatively weak observational evidence, rather than rigorous trials of purified CBD alone.
This distinction is important. Evidence that THC/CBD cannabis medicines can modestly reduce certain types of chronic pain does not automatically demonstrate that CBD by itself has the same effect. A 2025 U.S. evidence review found that some balanced THC/CBD preparations produced small reductions in chronic pain compared with placebo, but those findings concern products containing THC and should not be extrapolated directly to a zero-THC CBD tablet.
Why the TGA Application Is Unusual
TCann says it presented the PACT trial results to the TGA and the Department of Health, Disability and Ageing in July for consideration under Australia’s Provisional Registration Pathway. The provisional route allows promising prescription medicines addressing serious conditions to reach the market on preliminary evidence when regulators conclude that early access may offer substantial patient benefit. However, the TGA requires sponsors first to receive a provisional determination, and the regulator explicitly states that receiving such a determination does not guarantee that the eventual registration application will be accepted or approved.
The requirements are demanding. Applicants generally must show that a medicine addresses a life-threatening or seriously debilitating condition, is likely to provide a significant improvement over existing treatments, represents a major therapeutic advance and has a plan for producing comprehensive confirmatory safety and efficacy data. Even provisionally registered medicines must ultimately generate the evidence required for full registration. Initial provisional registration lasts two years and can, under defined circumstances, be extended to a maximum of six years.
That framework makes the failed Phase 3 primary endpoint especially relevant. TCann says the results have been submitted or presented for evaluation, but publicly available TGA material does not establish that the regulator has accepted the medicine for provisional registration. The company itself acknowledges the regulatory risk and notes that the TGA could decline to evaluate the trial under the requested pathway.
The Tablet Can Already Be Accessed Without Being an Approved Pain Medicine
Another easily misunderstood aspect of the story is that Australian patients can already receive many unregistered medicinal cannabis products through mechanisms such as the Special Access Scheme or Authorised Prescriber pathway. The TGA’s September 2026 medicinal cannabis list includes TCann CBD tablets among Category 1 products supplied through these systems. These programs allow doctors to obtain access to certain unapproved medicines for individual patients but do not mean the products have undergone the full safety, quality and efficacy evaluation required for ARTG registration.
Full registration would therefore be a major regulatory distinction. Instead of being an unapproved medicinal cannabis product supplied under an exception pathway, the tablet could become a formally evaluated medicine with a defined indication and standardized prescribing information. TCann ultimately also hopes to pursue easier pharmacy access, but Australia’s Schedule 3 rules still require a CBD medicine to be included on the ARTG before it can actually be sold as an approved pharmacist-only over-the-counter product. The TGA’s decision to permit doses up to 150 mg per day under Schedule 3 specifically noted that scheduling alone does not demonstrate efficacy or make a product available—the individual medicine must still prove itself through the registration process.
The Most Important Result May Be What the Next Trial Tests
Promethean and TCann have accomplished something relatively unusual in medicinal cannabis: they have taken a standardized, THC-free product through a randomized, placebo-controlled Phase 3 pain trial rather than relying primarily on observational evidence or patient reports. The trial appears to provide useful short-term safety data and generated a potentially interesting subgroup signal. But those achievements should not obscure its central efficacy result: 150 mg per day of the CBD tablet did not significantly outperform placebo for pain across the full study population.
That does not necessarily end development. In drug research, a failed broad trial can sometimes reveal that a treatment works only in a more narrowly defined disease subtype or patient population. The challenge now is to prospectively identify that population and reproduce the response in another properly controlled study. If the roughly 10-percent responder signal disappears, the Phase 3 result will look like another negative CBD pain trial. If it can be replicated under prespecified conditions, however, it could point toward a more targeted role for cannabidiol in pain medicine.
For now, the Australian tablet is best described as an investigational THC-free CBD medicine with encouraging formulation and safety characteristics, an intriguing exploratory responder signal—and a Phase 3 efficacy trial that did not achieve its primary endpoint. Whether that evidence is sufficient to support provisional Australian registration is now a regulatory question for the TGA, not a conclusion that can be drawn from the headline alone.
